

Arş.Gör.Dr. Naziye AK

Kişisel Bilgiler

İş Telefonu: [+90 212 414 2434](tel:+902124142434) Dahili: 34065

E-posta: naziye.ak@istanbul.edu.tr

Uluslararası Araştırmacı ID'leri

ORCID: 0000-0001-5790-7066

Publons / Web Of Science ResearcherID: AAP-3920-2020

Yoksis Araştırmacı ID: 178852

Eğitim Bilgileri

Tıpta Yandal Uzmanlık, İstanbul Üniversitesi, İstanbul Tıp Fakültesi-Onkoloji Enstitüsü, Tıbbi Onkoloji, Türkiye 2017 - Devam Ediyor

Tıpta Uzmanlık, İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Türkiye 2012 - 2016

Lisans, İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, İngilizce Tıp, Türkiye 2005 - 2011

Sertifika, Kurs ve Eğitimler

Eğitim Yönetimi ve Planlama, PSİKOONKOLOJİ 2. DÜZEY KLİNİSYEN EĞİTİMİ, PSİKONET-UZM. PSİKOLOG ESRA SAVAŞ KAPLAN BİREYSEL EĞİTİMİ, 2018

Eğitim Yönetimi ve Planlama, AİLE DANIŞMANLIĞI, ULUDAĞ ÜNİVERSİTESİ-UZAKTAN EĞİTİM, 2017

Sağlık ve Tıp, İMMUNOONKOLOJİ KURSU, TÜRK TIBBİ ONKOLOJİ DERNEĞİ, 2017

Eğitim Yönetimi ve Planlama, PSİKOONKOLOJİ 1. DÜZEY KLİNİSYEN EĞİTİMİ, PSİKONET-UZM. PSİKOLOG ESRA SAVAŞ KAPLAN BİREYSEL EĞİTİMİ, 2017

Yaptığı Tezler

Tıpta Uzmanlık, MEME KANSERİNDE NEOADJUVAN KEMOTERAPİ YANITINI PREDİKTE EDEN PATOLOJİK FAKTÖRLER , İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, 2016

Araştırma Alanları

Tıp, Sağlık Bilimleri, Dahili Tıp Bilimleri, İç Hastalıkları, Onkoloji

Akademik Unvanlar / Görevler

Araştırma Görevlisi, İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Tıbbi Onkoloji, 2017 - Devam Ediyor

SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler

1. The effect of parity, breastfeeding history, and duration on clinical and pathological characteristics

of breast cancer patients

Ak N., Tuz Z., Aydin E., Ferhatoğlu F., SARI M., Paksoy N., Doğan I., Yildiz A., Dişçi R., Saip P. M.
Turkish Journal of Medical Sciences, cilt.54, sa.1, ss.229-238, 2024 (SCI-Expanded)

- II. **Long-term outcomes and predictors of recurrence in node-negative early stage breast cancer patients**
DOĞAN İ., Aydin E., KHANMAMMADOV N., Paksoy N., Ferhatoğlu F., AK N., Emiroglu S., İBİŞ K., Onder S., Tukenmez M., et al.
Journal of Cancer Research and Clinical Oncology, cilt.149, sa.16, ss.14833-14841, 2023 (SCI-Expanded)
- III. **The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)**
Hizal M., Bilgin B., Paksoy N., Atci M. M., KAHRAMAN S., Kilickap S., Guven D. C., KESKİNKILIÇ M., Ayhan M., Eren O., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.149, sa.8, ss.4141-4148, 2023 (SCI-Expanded)
- IV. **Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study**
BAŞOĞLU TÜYLÜ T., Sakin A., Erol C., Ozden E., ÇABUK D., Cilbir E., Tataroglu ozyukseler D., Ayhan M., Sendur M. A., Dogan M., et al.
JOURNAL OF CHEMOTHERAPY, cilt.35, sa.2, ss.142-149, 2023 (SCI-Expanded)
- V. **Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study**
PAKSOY N., KHANMAMMADOV N., DOĞAN İ., FERHATOĞLU F., YILDIZ A., AK N., AYDINER A.
Medicine (United States), cilt.101, sa.45, 2022 (SCI-Expanded)
- VI. **The Predictive Importance of Body-Mass Index on Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer**
Emirzeoglu L., Arici S., Sahin A. B., Ocak B., Ak N., Ay S., Mammadov E., Turna H., Bilici A.
BREAST CARE, 2022 (SCI-Expanded)
- VII. **Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study**
Hizal M., Bilgin B., Paksoy N., Kilickap S., Atci M. M., KAHRAMAN S., KESKİNKILIÇ M., Bilgetekin I., Ayhan M., Tural D., et al.
FUTURE ONCOLOGY, cilt.18, ss.2573-2582, 2022 (SCI-Expanded)
- VIII. **Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.**
Dogan I., Paksoy N., Ak N., Vatansever S., Saip P., Aydin A.
JOURNAL OF CLINICAL ONCOLOGY, cilt.40, sa.16, 2022 (SCI-Expanded)
- IX. **The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study**
Hizal M., Bilgin B., Paksoy N., Acikgoz O., Sezer A., Gurbuz M., Ak N., Yucel S., Ayhan M., EROL C., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.148, sa.6, ss.1501-1508, 2022 (SCI-Expanded)
- X. **Prolongation of Neoadjuvant Chemotherapy before Surgery: Seeking the Optimal Number of Cycles in Serous Ovarian Cancer**
Minareci Y., Sozen H., Ak N., Tosun O. A., Saip P., Salihoglu M. Y., Topuz S.
CHEMOTHERAPY, cilt.67, ss.1-11, 2022 (SCI-Expanded)
- XI. **Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study**
Cil I., Kucukarda A., Atci M. M., Secmeler S., Paksoy N., Ferhatoglu F., Ak N., Ayhan M., Ozyukseler D. T., Onder A. H., et al.
TUMORI JOURNAL, cilt.108, sa.1, ss.19-25, 2022 (SCI-Expanded)
- XII. **Multidrug refractory aggressive metastatic TFE3 (+) renal cell carcinoma: A case report.**
Paksoy N., Erdem S., Karaca M., Ak N., Pehlivan M., Yirgin İ., Ozluk Y., Ekiz F., Tural D., Ekenel M., et al.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy

Practitioners, cilt.28, sa.1, ss.215-221, 2022 (SCI-Expanded)

- XIII. **Dramatic response to single-agent atezolizumab in a patient with MSI-H serous ovarian cancer**
Ak N., Vatansever S.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, cilt.46, sa.6, ss.1787-1791, 2021 (SCI-Expanded)
- XIV. **Nivolumab treatment for metastatic thymic epithelial tumors.**
Ak N., Aydinler A.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, cilt.27, ss.1710-1715, 2021 (SCI-Expanded)
- XV. **Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center**
Ak N., Toker A., Kara M., Ozkan B., Ulker M., Kaba E., Yegen G., Karaman S., Dagoglu N., Saglam E. K., et al.
TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, cilt.29, sa.4, ss.487-495, 2021 (SCI-Expanded)
- XVI. **Sentinel Lymph Node Biopsy May Prevent Unnecessary Axillary Dissection in Patients with Inflammatory Breast Cancer Who Respond to Systemic Treatment**
Karanlik H., CABIOĞLU N., Oprea A. L., ÖZGÜR İ., AK N., AYDINER A., ÖNDER S., BADEMLER S., GÜLLÜOĞLU M. B.
BREAST CARE, cilt.16, sa.5, ss.468-474, 2021 (SCI-Expanded)
- XVII. **Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy**
Oner G., Onder S., Karatay H., Ak N., Tukenmez M., Muslumanoglu M., Igci A., Dincag A., Ozmen V., Aydinler A., et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY, cilt.19, sa.1, 2021 (SCI-Expanded)
- XVIII. **Skeletal system as a rare metastatic site in patients with ovarian carcinoma**
Ak N., Minareci Y., Saip P.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, cilt.31, sa.8, ss.1125-1131, 2021 (SCI-Expanded)
- XIX. **Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors.**
Ferhatoglu F., Paksoy N., Dogan I., Ak N., Pehlivan M., Ekenel M., Basaran M.
JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021 (SCI-Expanded)
- XX. **Long-term outcomes and predictors of recurrence in patients with early-stage node negative breast cancer.**
Dogan I., Aydin E., Paksoy N., Ferhatoglu F., Ak N., Ibis K., Onder S., Tukenmez M., Cabioglu N., Muslumanoglu M., et al.
JOURNAL OF CLINICAL ONCOLOGY, cilt.39, sa.15, 2021 (SCI-Expanded)
- XXI. **The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study**
Ak N., Ozkan B., Yenigun M. B., Yilmazbayhan D., Toker A., Ferhatoglu F., Yasar A., SAK S., Tanju S., Dilege S., et al.
JOURNAL OF BUON, cilt.26, sa.3, ss.819-829, 2021 (SCI-Expanded)
- XXII. **Does visceral adiposity have an effect on the survival outcomes of the patients with endometrial cancer?**
Celik E., Kizildag Yirgin I., Goksever Celik H., Engin G., Sozen H., Ak N., Saip P., Onder S., Topuz S., Salihoglu M. Y.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, cilt.47, sa.2, ss.560-569, 2021 (SCI-Expanded)
- XXIII. **"Door to Treatment" Outcomes of Cancer Patients during the COVID-19 Pandemic**
Ak N., Vatansever S.
CHEMOTHERAPY, cilt.65, sa.5-6, ss.141-146, 2021 (SCI-Expanded)
- XXIV. **Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience**
Bahceci A., PAYDAŞ S., Ak N., Ferhatoglu F., Saip P. M., SEYDAOĞLU G., BİLİCİ M., ŞİMŞEK M., TEKİN S. B., Calikusu Z., et al.
CANCER INVESTIGATION, cilt.39, sa.6-7, ss.473-481, 2021 (SCI-Expanded)
- XXV. **Rapid drug desensitization for platinum-based chemotherapy drugs significantly increases peripheral blood IL-10 levels**
Tüzer C., Sarı M., Aktaş Ç., Ak N., Büyüköztürk S., Çolakoğlu B., Saip P., Deniz G., Gelincik A.

ALLERGY, cilt.75, sa.11, ss.2942-2946, 2020 (SCI-Expanded)

- XXVI. **Worse patient-physician relationship is associated with more fear of cancer recurrence (Deimos Study): A study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG)**
Alkan A., Yasar A., Guc Z. G., Gurbuz M., BAŞOĞLU TÜYLÜ T., SEZGİN GÖKSU S., Basal F. B., TÜRK H. M., Ozdemir O., Cinkir H. Y., et al.
EUROPEAN JOURNAL OF CANCER CARE, cilt.29, sa.6, 2020 (SCI-Expanded)
- XXVII. **IS CHEMOTHERAPY BETTER FOR EARLY STAGE HIGH RISK HISTOLOGIC TYPES OF ENDOMETRIAL CANCER**
ÇELİK E. G., AK N., SÖZEN H., SAİP P. M., TOPUZ S.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, cilt.29, 2019 (SCI-Expanded)
- XXVIII. **Outcomes of Thymoma and Determinants of Survival: 16 Years Experience of a Tertiary Cancer Center**
Ak N., Toker A., Bayraktar S., Ozkan B., Ülker M. B. C., Dagoglu N., Karaman S., Kaba E., Ferhatoglu F., Aydın E., et al.
JOURNAL OF THORACIC ONCOLOGY, sa.10, 2019 (SCI-Expanded)
- XXIX. **The Role Adjuvant Chemotherapy in Resected Stage 1 NSCLC with High Risk Factors: A Turkish Oncology Group Study**
Eralp Y., Ak N., Yilmazbayhan D., Ozkan B., Ferhatoglu F., Demirkazik A., Sak S. D., Dilege S., Tanju S., Toker A., et al.
JOURNAL OF THORACIC ONCOLOGY, cilt.14, sa.10, 2019 (SCI-Expanded)
- XXX. **Feasibility of sentinel lymph node biopsy in patients with node-positive inflammatory breast cancer who responded to neoadjuvant systemic treatment**
OPREA A. -, Ak N., Saip P., Onder S., Bademler S., Gulluoglu B. M., Karanlik H.
BREAST, cilt.44, 2019 (SCI-Expanded)
- XXXI. **Survival Impact of Optimal Surgical Cytoreduction in Recurrent Epithelial Ovarian Cancer with Brain Metastasis.**
Keskin S., Kucucuk S., Ak N., ATALAR B., Sari M., Sozen H., Ibis K., Topuz S., Saip P.
Oncology research and treatment, cilt.42, sa.3, ss.101-106, 2019 (SCI-Expanded)

Diğer Dergilerde Yayınlanan Makaleler

- I. **Prognostic Value of p16INK4A and Ki67 Co-expression in Patients with Vaginal Intraepithelial Neoplasia**
Minareci Y., AK N., Bayram A., Tosun O. A., Murdan R., Onder S., Sozen H., Topuz S., Salihoglu M. Y.
Indian Journal of Gynecologic Oncology, cilt.22, sa.2, 2024 (ESCI)
- II. **Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine**
DOĞAN İ., Paksoy N., AK N., VATANSEVER S., Saip P., AYDINER A.
European Journal of Breast Health, cilt.19, sa.2, ss.128-133, 2023 (Scopus)
- III. **Predictors of high-grade residual disease after repeat conization in patients with positive surgical margins**
Minareci Y., AK N., Tosun O. A., Sozen H., Disci R., Topuz S., Salihoglu M. Y.
Ginekologia polska, cilt.93, sa.12, ss.962-967, 2022 (Scopus)
- IV. **Effect of Astragalus Membranaceus on Patients with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study**
Ak N., Ciftci R., Cabioglu N., Aydinler A.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, cilt.36, sa.2, ss.215-221, 2021 (ESCI)
- V. **Nectin-2 and Nectin-4 Adhesion Molecules in Patients with Breast Cancer**
Ak N., Serilmez M., Ucuncu M. Z., Bademler S., Vatansever S.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, cilt.36, sa.2, ss.165-170, 2021 (ESCI)

Kitap & Kitap Bölümleri

I. Endometrium Kanseri

AK N.

Klinik Çalışmalarla Onkolojide Hedefli Tedaviler, CİHAN S, GEREDİLİ Ç, DEMİR C., Editör, Tıbbi Yayınlar Merkezi, İstanbul, ss.113-122, 2019

II. Systemic Treatment Drugs/Regimens and Dose Modifications

AK N.

Breast Disease, Aydinler A., Igci A., Soran A., Editör, Springer, Cham, İsviçre, ss.789-801, 2019

III. Systemic Treatment Drugs and Regimens

AK N.

Breast Cancer A Guide to Clinical Practice, Aydinler A, Igci A, Soran A., Editör, Springer International Publishing, Copyright Holder Springer Nature Switzerland Ag, ss.587-608, 2018

Hakemli Kongre / Sempozyum Bildiri Kitaplarında Yer Alan Yayınlar

- I. **Clinicopathologic features and prognostic factors in male breast cancer: A single centre experience**
DOĞAN İ., AYDIN E. M., AK N., İBİŞ K., Sukruoglu Ö., Erciyas S., YAZICI H., AYDINER A., SAİP P. M.
ESMO Asia Virtual Congress, ELECTR NETWORK, 20 - 22 Kasım 2020, cilt.31
- II. **Does nutritional status affect treatment tolerability, response and survival in metastatic gastric cancer patients? Results of prospective multicenter study**
Karabulut S., Dogan I., Ak N., Afsar C. U., Karabulut M., Tastekin D.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, cilt.30, ss.305
- III. **Does nutritional status affect treatment tolerability, response and survival in metastatic gastric cancer patients? Results of prospective multicenter study**
AK N.
European Society for Medical Oncology Congress 2019, Barcelona, İspanya, 27 Eylül - 01 Ekim 2019, ss.424-430
- IV. **THE ROLE ADJUVANT CHEMOTHERAPY IN RESECTED STAGE 1 NSCLC WITH HIGH RISK FACTORS: A TURKISH ONCOLOGY GROUP STUDY**
AK N.
World Conference of Lung Cancer 2019, Barcelona, İspanya, 7 - 10 Eylül 2019, ss.933-934
- V. **OUTCOMES OF THYMOMA AND DETERMINANTS OF SURVIVAL: 16 YEARS EXPERIENCE OF A TERTIARY CANCER CENTER**
AK N.
World Conference of Lung Cancer, Barcelona, İspanya, 7 - 10 Eylül 2019, ss.1095-1096
- VI. **Rapid drug desensitization for platinum-based chemotherapy drugs significantly increases peripheral blood IL-10 levels**
Tuzer O. C., Sari M., Aktas E., Ak N., Buyukozturk S., Colakoglu B., Saip P. M., Deniz G., Gelincik A.
Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Lisbon, Portekiz, 1 - 05 Haziran 2019, cilt.74, ss.737-738
- VII. **Significance of adiposity in endometrial cancer prognosis.**
KIZILDAĞ YIRGIN İ., ENGİN G., ÇELİK E., TOPUZ S., AK N., SAİP P.
Türk manyetik rezonans derneği.24.Uluslararası katılımlı yıllık bilimsel toplantısı. 2019, Ankara, Türkiye, 25 - 27 Nisan 2019
- VIII. **Platin ile hızlı desensitizasyonun sitokin düzeylerine etkisi P -29**
Tüzer Ö. C., Sarı M., ÇETİN E., Ak N., BÜYÜKÖZTÜRK S., ÇOLAKOĞLU B., Saip P. M., DENİZ G., GELİNCİK A.
XXV. Ulusal Alerji ve Klinik İmmünoloji Kongresi, Antalya, Türkiye, 17 - 21 Kasım 2018, ss.111
- IX. **IVIG sonrası akut miyokard enfarktüsü gelişen iki ITP olgusu**
BAVUNOĞLU İ., EYİCE D., AK N., ELVERDİ T., EŞKAZAN A. E., AR M. C., TUNÇKALE A., BAŞLAR Z., ÖNGÖREN Ş.

39. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 23 - 26 Ekim 2013, sa.261, ss.277-278

X. IVIG sonrası akut miyokard enfarktüsü gelişen iki ITP olgusu

BAVUNOĞLU I., EYİCE D., AK N., ELVERDİ T., EŞKAZAN A. E., AR M. C., TUNÇKALE A., BAŞLAR Z., ÖNGÖREN Ş.

38. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 31 Ekim - 03 Kasım 2012, sa.261, ss.277-278

Bilimsel Kuruluşlardaki Üyelikler / Görevler

Türk Tıbbi Onkoloji Derneği, Üye, 2019 - Devam Ediyor

Bilimsel Hakemlikler

21st World Congress of Psycho-Oncology /Abstract Reviewer, Diğer Dergiler, Eylül 2019

Metrikler

Yayın: 49

Atıf (WoS): 54

Atıf (Scopus): 52

H-İndeks (WoS): 4

H-İndeks (Scopus): 4